Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
Silvia La MonicaDaniele CretellaMara BonelliClaudia FumarolaAndrea CavazzoniGraziana DigiacomoLisa FlamminiElisabetta BarocelliRoberta MinariNadia NaldiPier Giorgio PetroniniMarcello TiseoRoberta AlfieriPublished in: Journal of experimental & clinical cancer research : CR (2017)
Our data suggest that concomitant treatment with osimertinib and T-DM1 may be a promising therapeutic strategy for EGFR-mutant NSCLC.